Loading stock data…
$2.53-0.05 (-1.94%)
Niagen Bioscience, Inc.
Niagen Bioscience, Inc. in the Consumer Defensive sector is trading at $2.53 with a market capitalization of $245M. Wall Street consensus targets $12.08 (6 analysts), implying a +377.6% move over the next 12 months. The stock is currently near its 52-week low of $2.51, remaining 39.2% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 24 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $29.79M↓ | $31.47M↓ | $33.84M↓ | $33.99M↑ | $31.12M |
| Gross Profit | $19.31M↓ | $19.98M↓ | $21.70M↓ | $21.93M↑ | $20.23M |
| Operating Income | $700,000↓ | $1.58M↓ | $2.10M↓ | $4.24M↑ | $3.19M |
| Net Income | $963,000↓ | $6.32M↑ | $4.13M↓ | $4.58M↑ | $3.61M |
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that con...